Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun;14(2):87-93.
doi: 10.1097/SPC.0000000000000493.

Cannabis and cannabinoids in cancer pain management

Howard Meng  1 , Tianyang Dai  2 , John G Hanlon  1   3 , James Downar  4   5 , Shabbir M H Alibhai  6 , Hance Clarke  1   7   8
Affiliations
Review

Cannabis and cannabinoids in cancer pain management

Howard Meng et al. Curr Opin Support Palliat Care. 2020 Jun.

Abstract

Purpose of review: An increasing number of patients are turning to cannabis and cannabinoids for management of their palliative and nonpalliative cancer pain and other cancer-related symptoms. Canadians have a legal framework for access to medical cannabis, which provides a unique perspective in a setting lacking robust clinical evidence. This review seeks to delineate the role of cannabis and cannabinoids in cancer pain management and offers insight into the Canadian practice.

Recent findings: A cohort study using nabiximols on advanced cancer pain in patients already optimized on opioids, over 3 weeks, demonstrated improved average pain score. A large observational study of cancer patients using cannabis over 6 months demonstrated a decreased number of patients with severe pain and decreased opioid use, whereas the number of patients reporting good quality of life increased.

Summary: Good preclinical animal data and a large body of observational evidence point to the potential efficacy of cannabinoids for cancer pain management. However, there are relatively weak data pointing to clinical efficacy from clinical trial data to date. In Canada, the burgeoning cannabis industry has driven the population to embrace a medicine before clinical evidence. There remains a need for high-quality randomized controlled trials to properly assess the effectiveness and safety of medical cannabis, compared with placebo and standard treatments for cancer-related symptoms.

PubMed Disclaimer

References

    1. World: Drug Report 2019. Vienna, Austria: United Nations; 2019.
    1. Aizpurua-Olaizola O, Soydaner U, Öztürk E, et al. Evolution of the cannabinoid and terpene content during the growth of cannabis sativa plants from different chemotypes. J Nat Prod 2016; 79:324–331.
    1. Ablin J, Ste-Marie PA, Schafer M, et al. Medical use of cannabis products: lessons to be learned from Israel and Canada. Schmerz 2016; 30:3–13.
    1. Chen JW, Borgelt LM, Blackmer AB. Cannabidiol: a new hope for patients with Dravet or Lennox-Gastaut syndromes. Ann Pharmacother 2019; 53:603–611.
    1. Hill KP, Palastro MD, Johnson B, et al. Cannabis and pain: a clinical review. Cannabis Cannabinoid Res 2017; 2:96–104.

Publication types